Beringer PM - Search Results

1

Engineered Cyclotides with Potent Broad in Vitro and in Vivo Antimicrobial Activity.

Ganesan R, Dughbaj MA, Ramirez L, Beringer S, Aboye TL, Shekhtman A, Beringer PM, Camarero JA. Ganesan R, et al. Among authors: beringer s, beringer pm. Chemistry. 2021 Sep 1;27(49):12702-12708. doi: 10.1002/chem.202101438. Epub 2021 Aug 6. Chemistry. 2021. PMID: 34159664 Free PMC article.

2

Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.

Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. Beringer PM, et al. J Antimicrob Chemother. 2016 Jan;71(1):181-8. doi: 10.1093/jac/dkv301. Epub 2015 Oct 3. J Antimicrob Chemother. 2016. PMID: 26433781 Free PMC article.

3

Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis.

Dughbaj MA, Jayne JG, Park AYJ, Bensman TJ, Algorri M, Ouellette AJ, Selsted ME, Beringer PM. Dughbaj MA, et al. Among authors: beringer pm. Antibiotics (Basel). 2021 Aug 26;10(9):1043. doi: 10.3390/antibiotics10091043. Antibiotics (Basel). 2021. PMID: 34572625 Free PMC article.

4

Chemical Synthesis of a Potent Antimicrobial Peptide Murepavadin Using a Tandem Native Chemical Ligation/Desulfurization Reaction.

Chaudhuri D, Ganesan R, Vogelaar A, Dughbaj MA, Beringer PM, Camarero JA. Chaudhuri D, et al. Among authors: beringer pm. J Org Chem. 2021 Nov 5;86(21):15242-15246. doi: 10.1021/acs.joc.1c01858. Epub 2021 Oct 12. J Org Chem. 2021. PMID: 34641669 Free PMC article.

5

Economic aspects of antibacterial adverse effects.

Beringer PM, Wong-Beringer A, Rho JP. Beringer PM, et al. Pharmacoeconomics. 1998 Jan;13(1 Pt 1):35-49. doi: 10.2165/00019053-199813010-00004. Pharmacoeconomics. 1998. PMID: 10175984 Review.

6

New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis.

Beringer PM. Beringer PM. Curr Opin Pulm Med. 1999 Nov;5(6):371-7. doi: 10.1097/00063198-199911000-00009. Curr Opin Pulm Med. 1999. PMID: 10570739 Review.

7

Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Aminimanizani A, Beringer P, Jelliffe R. Aminimanizani A, et al. Clin Pharmacokinet. 2001;40(3):169-87. doi: 10.2165/00003088-200140030-00003. Clin Pharmacokinet. 2001. PMID: 11327197 Review.

8

The clinical use of colistin in patients with cystic fibrosis.

Beringer P. Beringer P. Curr Opin Pulm Med. 2001 Nov;7(6):434-40. doi: 10.1097/00063198-200111000-00013. Curr Opin Pulm Med. 2001. PMID: 11706322 Review.

9

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.

Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Montgomery MJ, et al. Among authors: beringer pm. Antimicrob Agents Chemother. 2001 Dec;45(12):3468-73. doi: 10.1128/AAC.45.12.3468-3473.2001. Antimicrob Agents Chemother. 2001. PMID: 11709326 Free PMC article. Clinical Trial.

10

Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.

Bensman TJ, Jayne JG, Sun M, Kimura E, Meinert J, Wang JC, Schaal JB, Tran D, Rao AP, Akbari O, Selsted ME, Beringer PM. Bensman TJ, et al. Among authors: beringer pm. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00154-17. doi: 10.1128/AAC.00154-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28559270 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters